These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 70286)

  • 61. Assessment of Hereditary Thrombophilia: Performance of Antithrombin (AT) Testing.
    Gausman JN; Marlar RA
    Methods Mol Biol; 2017; 1646():161-167. PubMed ID: 28804827
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effect of sulfated xylans during the interaction of [125I]-thrombin with antithrombin III or heparin cofactor II of human plasma.
    Simmons RB; Newton GR; Doctor VM
    Eur J Drug Metab Pharmacokinet; 1995; 20(1):73-7. PubMed ID: 7588997
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Thrombin-based antithrombin assays show overestimation of antithrombin III activity in patients on heparin therapy due to heparin cofactor II influence.
    Bohner J; von Pape KW; Blaurock M
    Thromb Haemost; 1994 Mar; 71(3):280-3. PubMed ID: 8029789
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Esterolytic method for determination of heparin in plasma.
    Kapke GF; Feld RD; Witte DL; Owen WG
    Clin Chem; 1981 Apr; 27(4):526-9. PubMed ID: 7471418
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Heparin cofactor II is degraded by heparan sulfate and dextran sulfate.
    Saito A
    Biochem Biophys Res Commun; 2015 Feb; 457(4):585-8. PubMed ID: 25600805
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Inhibition of heparin-catalyzed human antithrombin III activity by nonenzymatic glycosylation. Possible role in fibrin deposition in diabetes.
    Brownlee M; Vlassara H; Cerami A
    Diabetes; 1984 Jun; 33(6):532-5. PubMed ID: 6724150
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Heparin cofactor activity during and after extracorporeal circulation with bubble and membrane oxygenators.
    Weiss M; Blass J; Leau A; Verriest C
    Biomedicine; 1977 Oct; 27(7):248-9. PubMed ID: 73390
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Use of N-benzoyl-phenylalanyl-valyl-arginine p-nitroanilide and hirudin for the detection of enzymatic activity under prothrombin acylation by citraconic anhydride].
    Baskova IP; Memon MS; Cherkesova DU
    Biokhimiia; 1977 Aug; 42(8):1487-90. PubMed ID: 562196
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Development and analytical performance of automated tests for antithrombin III and plasminogen on the Du Pont aca analyzer.
    Perry JF; Siefring GE; Reider MC; Coleman PL; Wehrly JA
    Clin Chem; 1983 Apr; 29(4):609-13. PubMed ID: 6831687
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Comparison of immunochemical and biological properties of human anti thrombin during blood clotting and upon interaction with exogenous thrombin.
    Esnard F; Gauthier F; Mouray H
    Thromb Res; 1983 Jul; 31(1):127-33. PubMed ID: 6612691
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Improved assay of antithrombin-III. Effects of certain additives on thrombin and on chromogenic peptide substrates.
    Gram J; Jespersen J
    Clin Chem; 1985 Oct; 31(10):1683-8. PubMed ID: 4042332
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Comparison of progressive antithrombin activity and the concentration of three thrombin inhibitors in human plasma.
    Abildgaard U; Fagerhol MK; Egeberg O
    Scand J Clin Lab Invest; 1970 Dec; 26(4):349-54. PubMed ID: 4098730
    [No Abstract]   [Full Text] [Related]  

  • 73. [A method for isolated determination of thrombin inhibitor and antithrombin].
    WITTE S; DIRNBERGER P
    Klin Wochenschr; 1953 Jul; 31(25-26):598-600. PubMed ID: 13097856
    [No Abstract]   [Full Text] [Related]  

  • 74. An automated amidolytic assay of thrombin generation: an alternative for the prothrombin-time test.
    Paulssen MM; Kolhorn A; Rothuizen J; Planje MC
    Clin Chim Acta; 1979 Mar; 92(3):465-8. PubMed ID: 436285
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Congenital disorders of glycosylation as an unusual cause of antithrombin deficiency and elevated thrombin generation.
    Hasan R; Kayani S; Zia A
    Pediatr Blood Cancer; 2020 Feb; 67(2):e28069. PubMed ID: 31736265
    [No Abstract]   [Full Text] [Related]  

  • 76. [New determination method and clinical significance of antithrombin].
    JURGENS J
    Klin Wochenschr; 1957 Mar; 35(6):303-8. PubMed ID: 13429825
    [No Abstract]   [Full Text] [Related]  

  • 77. An improved method for plasma fibrinogen based on thrombin time measurement.
    Saleem A; Fretz K
    Clin Chim Acta; 1975 Jul; 62(1):131-6. PubMed ID: 1149268
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Solid-phase synthesis of thrombin inhibitors.
    Lange UE; Zechel C
    Bioorg Med Chem Lett; 2002 Jun; 12(12):1571-3. PubMed ID: 12039564
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Heparin cofactor II activity in plasma: application of an automated assay method to the study of a normal adult population.
    Andersson TR; Larsen ML; Handeland GF; Abildgaard U
    Scand J Haematol; 1986 Jan; 36(1):96-102. PubMed ID: 3754062
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Effects of a large dose of oestradiol on antithrombin III metabolism in male and female dogs.
    Kobayashi N; Takeda Y
    Eur J Clin Invest; 1977 Oct; 7(5):373-81. PubMed ID: 411666
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.